Low-intensity treatment of hematological disorders
AssigneeCelator Pharmaceuticals, Inc.
InventorsRonald CHEUNG, Stefan FADERL, Qi WANG
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions and methods for treating patients with hematological proliferative disorders who are ineligible for treatment with standard intensive chemotherapy, using low intensity treatment with CPX-351, a liposomal composition of daunorubicin and cytarabine.
Claims11
1-11. (canceled)
A method to treat a hematologic proliferative disorder in a subject ineligible for standard intensive chemotherapy (an ISICT subject), which method comprises administering to said subject a pharmaceutical composition comprising CPX-351 as the sole active ingredient that supplies daunorubicin and cytarabine in a treatment cycle that comprises delivering less than 300 mg/m2 of cytarabine over the course of the treatment cycle, wherein the hematologic proliferative disorder is acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), acute promyelocytic leukemia (APL), or myeloproliferative neoplasm (MPN).
19-20. (canceled)
Dependencies are inferred from the claim text.